UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

Body-Weight Fluctuations and Outcomes in Coronary Disease

The New England journal of medicine, 2017-04, Vol.376 (14), p.1332-1340

2017

Link zum Volltext

Verfügbarkeit prüfen

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Circulation (New York, N.Y.), 2018-08, Vol.138 (8), p.770-781

2018

Link zum Volltext

Verfügbarkeit prüfen

Quality-of-Life Impairment in Depressive and Anxiety Disorders

The American journal of psychiatry, 2005-06, Vol.162 (6), p.1171-1178

2005

Link zum Volltext

Verfügbarkeit prüfen

Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD

American journal of kidney diseases, 2009-05, Vol.53 (5), p.741-750

2009

Link zum Volltext

Verfügbarkeit prüfen

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease

The American journal of medicine, 2014, Vol.127 (1), p.71-81.e1

2014

Link zum Volltext

Verfügbarkeit prüfen

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?

The American journal of medicine, 2016-04, Vol.129 (4), p.384-391

2016

Link zum Volltext

Verfügbarkeit prüfen

Visit-to-visit variability of lipid measurements as predictors of cardiovascular events

Journal of clinical lipidology, 2018-03, Vol.12 (2), p.356-366

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of Female Sex on Lipid Lowering, Clinical Outcomes, and Adverse Effects in Atorvastatin Trials

The American journal of cardiology, 2015-02, Vol.115 (4), p.447-453

2015

Link zum Volltext

Verfügbarkeit prüfen

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

Heart (British Cardiac Society), 2015-03, Vol.101 (5), p.356-362

2015

Link zum Volltext

Verfügbarkeit prüfen

Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder

Journal of clinical psychopharmacology, 2014-02, Vol.34 (1), p.57-65

2014

Link zum Volltext

Verfügbarkeit prüfen

Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials

The American journal of cardiology, 2014-06, Vol.113 (12), p.2018-2020

2014

Link zum Volltext

Verfügbarkeit prüfen

Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION

Clinical trials (London, England), 2020-10, Vol.17 (5), p.535-544

2020

Link zum Volltext

Verfügbarkeit prüfen

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

The American journal of cardiology, 2009-08, Vol.104 (4), p.459-463

2009

Link zum Volltext

Verfügbarkeit prüfen

Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial

Drugs & aging, 2015-12, Vol.32 (12), p.1055-1065

2015

Link zum Volltext

Verfügbarkeit prüfen

Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials

Journal of the American Heart Association, 2019-05, Vol.8 (9), p.e010827

2019

Link zum Volltext

Verfügbarkeit prüfen

Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder

CNS spectrums, 2014-12, Vol.19 (6), p.519-527

2014

Link zum Volltext

Verfügbarkeit prüfen

Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis

International clinical psychopharmacology, 2012-01, Vol.27 (1), p.1

2012

Link zum Volltext

Verfügbarkeit prüfen

The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies

Human psychopharmacology, 2014-09, Vol.29 (5), p.492-501

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies

International clinical psychopharmacology, 2013-11, Vol.28 (6), p.312

2013

Link zum Volltext

Verfügbarkeit prüfen

A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d

Primary care companion for CNS disorders, 2015, Vol.17 (3)

2015

Link zum Volltext

Verfügbarkeit prüfen

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin

Journal of the American Heart Association, 2018-01, Vol.7 (2), p.n/a

2018

Link zum Volltext

Verfügbarkeit prüfen

Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma

Human pathology, 2006, Vol.37 (1), p.9-15

2006

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4825-4832

2006

Link zum Volltext

Verfügbarkeit prüfen

An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder

Primary care companion for CNS disorders, 2015, Vol.17 (1)

2015

Link zum Volltext

Verfügbarkeit prüfen

Comparison of One-Year Efficacy and Safety of Atorvastatin Versus Lovastatin in Primary Hypercholesterolemia

The American journal of cardiology, 1997-06, Vol.79 (11), p.1475-1481

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(79)

Publikationsform

Sprache

Englisch
(94)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(66)
Life Sciences & Biomedicine
(65)
Humans
(56)
Female
(50)
Male
(46)
Middle Aged
(39)
Aged
(29)
Adult
(28)
Treatment Outcome
(26)
Biological And Medical Sciences
(24)
Medical Sciences
(24)
Double-Blind Method
(23)
Cardiac & Cardiovascular Systems
(21)
Cardiovascular System & Cardiology
(21)
Psychiatry
(19)
Cardiovascular Disease
(15)
Antidepressive Agents - Therapeutic Use
(13)
Dose-Response Relationship, Drug
(13)
Psychology. Psychoanalysis. Psychiatry
(13)
Depressive Disorder, Major - Drug Therapy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Body-Weight Fluctuations and Outcomes in Coronary Disease

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Quality-of-Life Impairment in Depressive and Anxiety Disorders

Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?

Visit-to-visit variability of lipid measurements as predictors of cardiovascular events

Impact of Female Sex on Lipid Lowering, Clinical Outcomes, and Adverse Effects in Atorvastatin Trials

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder

Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials

Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial

Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials

Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder

Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis

The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies

A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin

Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma

Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non–Small-Cell Lung Cancer

An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder

Comparison of One-Year Efficacy and Safety of Atorvastatin Versus Lovastatin in Primary Hypercholesterolemia

Suchergebnisse filtern